LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $8,720 | -7.6% | 8,000 | 0.0% | 0.01% | -14.3% |
| Q3 2023 | $9,440 | -16.3% | 8,000 | 0.0% | 0.01% | -12.5% |
| Q2 2023 | $11,280 | +93900.0% | 8,000 | 0.0% | 0.01% | -11.1% |
| Q1 2023 | $12 | +33.3% | 8,000 | 0.0% | 0.01% | +28.6% |
| Q4 2022 | $9 | -99.9% | 8,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $9,000 | -30.8% | 8,000 | 0.0% | 0.01% | -30.0% |
| Q2 2022 | $13,000 | -35.0% | 8,000 | 0.0% | 0.01% | -23.1% |
| Q1 2022 | $20,000 | 0.0% | 8,000 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $20,000 | +53.8% | 8,000 | +61.0% | 0.01% | +44.4% |
| Q3 2021 | $13,000 | -7.1% | 4,970 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $14,000 | +16.7% | 4,970 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $12,000 | +33.3% | 4,970 | 0.0% | 0.01% | +50.0% |
| Q4 2020 | $9,000 | +125.0% | 4,970 | 0.0% | 0.01% | +50.0% |
| Q1 2020 | $4,000 | 0.0% | 4,970 | 0.0% | 0.00% | +33.3% |
| Q4 2019 | $4,000 | -20.0% | 4,970 | 0.0% | 0.00% | -25.0% |
| Q3 2019 | $5,000 | – | 4,970 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
| BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
| Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
| Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
| Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
| Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
| DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
| Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |